In addressing these issues, we found that treatment of that deamidation of these asparagines imports susseveral types of tumor cells with DNA-damaging agents ceptibility to apoptosis by disrupting the ability of induces deamidation of two asparagines in the unstrucBcl-x L to block the proapoptotic activity of BH3 dotured loop of Bcl-x L . We demonstrate that deamidation main-only proteins. Conversely, Bcl-x L deamidation is completely disrupts the antiapoptotic activity of Bcl-x L , actively suppressed in fibroblasts, and suppression of and that this occurs because it disrupts the ability of deamidation is an essential component of their resisBcl-x L to block the proapoptotic activity of BH3 domaintance to DNA damage-induced apoptosis. Our results only Bcl-2 proteins. Importantly, we show that Bcl-x L suggest that the regulation of Bcl-x L deamidation has deamidation is actively suppressed in growth-arrested a critical role in the tumor-specific activity of DNAfibroblasts, which is indeed critical for the suppression damaging antineoplastic agents.
Introduction Results

DNA-damaging antineoplastic agents are effective be-
Rb-Mediated Arrest of Tumor Cells Suppresses cause they induce tumor cell apoptosis (Schmitt and a DNA-Damaging Antineoplastic Agent-Induced Lowe, 1999). Most tumor cells lack wild-type p53 activity
Modification of Bcl-x L (Evan and Vousden, 2001), and therefore p53-indepenSome antineoplastic agents damage the DNA of normal dent signaling pathways must be of primary importance as well as tumor cells, but selectively cause tumor cell in tumor cell apoptosis. These pathways are presumably apoptosis. Most tumors lack Rb activity; however, Rb intact in the cells of normal tissue; however, apoptotic is present in all normal tissue (Nevins, 2001), and it is a signaling is suppressed in many of these cells. For expotent antiapoptotic protein (Haas-Kogan et al., 1995). ample, fibroblasts arrest without undergoing apoptosis Therefore, we considered the possibility that Rb has a in response to DNA damage (Di Leonardo et al., 1994) , role in the tumor cell selectivity of such antineoplastic and high concentrations of cisplatin-DNA adducts accuagents. mulate in many tissues, not just in the malignant tissue, To begin to determine the mechanism by which DNA during cisplatin treatment (Poirier et al., 1987 (Poirier et al., , 1992 ; Terdamage selectively induces tumor cell death, we generheggen et al., 1987), yet cisplatin treatment does not ated a p53 null, Rb null osteosarcoma cell line (SAOS-2) cause apoptosis in most normal tissue. We sought to in which Rb expression is inducible. Whereas SAOS-2 determine the mechanism by which DNA-damaging ancells were susceptible to cisplatin-induced apoptosis, cisplatin-induced apoptosis was blocked by Rb expression ( Figure 1A ). We next sought to identify cisplatin-induced proapoptotic signals that are suppressed by expression of Rb. Rb expression had no affect on cisplatin-DNA adduct formation ( Figure 1B) , and we have found that induction of Rb expression in SAOS-2 cells even as late as 12 hr after the cells were ␥ irradiated efficiently protected them from ␥ radiation-induced apoptosis (data not shown). We next found that Rb expression blocks cisplatin-induced mitochondrial cytochrome c release ( Figure 1C ). Based on these findings, we hypothesized that Rb suppresses a proapoptotic signal(s) that is either parallel to or downstream of DNA damage, but upstream of mitochondrial cytochrome c release during the cisplatin-induced apoptotic response in SAOS-2 cells. We found that the Bcl-x L modification that occurs during cisplatin-induced apoptosis does not occur during BIMinduced apoptosis ( Figure 1F Figure 6A) , we thought it so we considered the possibility that Rb might inhibit fibroblast apoptosis in part because it suppresses denotable that inactivation of p53 renders NHDFs and MEFs susceptible to DNA-damaging agents ( Figure 5D ; amidation of Bcl-x L . Therefore, we sought to determine the role of Rb in the regulation of deamidation of Bcl-x L Fan et al., 1995; Hawkins et al., 1996) (we note that it has been reported that wild-type fibroblasts are more in fibroblasts.
Several DNA-damaging agents have been found to sensitive to DNA-damaging agents than p53 Ϫ/Ϫ MEFs; however, the cells used in the study were transformed induce activation (dephosphorylation) of fibroblast Rb (Slebos et al., 1994) . We wanted to confirm that Rb with the viral oncogene E1a [Lowe et al., 1993]). We hypothesized that p53 Ϫ/Ϫ fibroblasts are susceptible to is active in cisplatin-treated MEFs. Rb rapidly became dephosphorylated upon cisplatin treatment ( Figure 6A) . cisplatin-induced apoptosis, at least in part, because the lack of Rb activation in these cells would be permisCyclin A expression is downregulated in response to DNA damage in an Rb-dependent manner (Knudsen et sive for Bcl-x L deamidation in the same manner that the lack of Rb activation is permissive for expression of al., 1999). Cyclin A was downregulated by cisplatin treatment, confirming that Rb is active in cisplatin-treated cyclin A in cisplatin-treated p53 Ϫ/Ϫ MEFs. Indeed, whereas cisplatin treatment had no effect on MEFs ( Figure 6A ). Because DNA-damaging agents fail to activate Rb in cells lacking p53 (Slebos et al., 1994) , the Bcl-x L in wild-type MEFs, the Bcl-x L from cisplatin- MEFs as resistant to cisplatin as wild-type MEFs, olomoucine failed to confer the same level of resistance to the p53 Ϫ/Ϫ , bcl-x Ϫ/Ϫ MEFs as it did to p53 Ϫ/Ϫ MEFs (Figure 6E) . Therefore, if Bcl-x L is inactivated, olomoucine is ineffective in blocking cisplatin-induced apoptosis of MEFs that lack p53. Because deamidation of Bcl-x L results in the inactivation of Bcl-x L (Figure 4A ), these results indicated that suppression of Bcl-x L deamidation is critical for the suppression of cisplatin-induced apoptosis in fibroblasts. ), yet fibroblasts growth arrest without undergoing apoptosis in response to DNA damage (Di Leonardo et al., 1994) . We hypothesized that the upregulation of BH3 domain-only protein expression is the second proapoptotic signal, and that functional Bcl-x L is required to suppress their proapoptotic activity for fibroblasts to maintain resistance to apoptosis. Therefore, we examined Bcl-x L regulation of NOXA activity during the fibroblast response to cisplatin.
Suppression of
We first established that NOXA is upregulated by a concentration of cisplatin that does not normally induce apoptosis of NHDFs ( Figure 7A ). We then examined the 
